Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: A comparative analysis of different postoperative management strategies Journal Article


Authors: Touijer, K. A.; Karnes, R. J.; Passoni, N.; Sjoberg, D. D.; Assel, M.; Fossati, N.; Gandaglia, G.; Eastham, J. A.; Scardino, P. T.; Vickers, A.; Cozzarini, C.; Montorsi, F.; Briganti, A.
Article Title: Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: A comparative analysis of different postoperative management strategies
Abstract: Background: Optimal management of patients with lymph node metastasis (LNM) after radical prostatectomy (RP) remains undefined. Objective: We evaluated the association between three different management strategies and survival in prostate cancer with LNM after RP. Design, setting, and participants: We analyzed data of 1338 patients with LNM after RP from three tertiary care centers. Three hundred and eighty-seven patients (28%) were observed, 676 (49%) received lifelong adjuvant androgen deprivation therapy (ADT), and 325 (23%) received adjuvant external beam radiation therapy (EBRT) and ADT. Three hundred and sixty-eight men were followed for more than 10 yr. Outcome measurements and statistical analysis: Primary outcome measure was overall survival (OS). Secondary outcomes were cancer-specific survival (CSS) and other-cause mortality. Kaplan-Meier methods were used to visualize OS for the three treatment groups. Cox proportional hazards regression was utilized to compare OS and CSS among the three groups. Results and limitations: ADT + EBRT was associated with better OS than ADT alone (hazard ratio [HR]: 0.46, 95% confidence interval [CI]: 0.32–0.66, p < 0.0001) or observation (HR: 0.41, 95% CI: 0.27–0.64, p < 0.0001). Higher-risk patients benefited more from ADT + EBRT than lower-risk patients. Ten-year mortality risk difference between ADT + EBRT, observation, or ADT alone ranged from 5% in low-risk patients to 40% in high-risk patients. Adjuvant ADT + EBRT was also associated with better CSS than observation or ADT alone (p < 0.0001), ADT had better CSS compared to observation (HR: 0.64, 95% CI: 0.43–0.95, p = 0.027). However, ADT was associated with an increased risk of other-cause mortality (HR: 3.05, 95% CI: 1.45–6.40, p = 0.003) compared with observation, resulting in similar OS between ADT and observation (HR: 0.90, 95% CI: 0.65–1.25, p = 0.5). While selection bias might remain, its effect would operate in the opposite direction to our findings. Conclusions: In men with LNM after RP, ADT + EBRT improved survival over either observation or adjuvant ADT alone. This survival benefit increases with higher-risk disease. Patient summary: Lymph node metastasis following radical prostatectomy is associated with poor survival outcomes. However, we found that adjuvant androgen deprivation therapy with external beam radiation therapy improved survival in these patients. Lymph node metastasis following radical prostatectomy is associated with poor survival outcomes. Adjuvant androgen deprivation therapy with external beam radiation therapy confers a long-term overall survival advantage than either observation or androgen deprivation therapy alone. © 2017 European Association of Urology
Keywords: adult; aged; middle aged; cancer surgery; major clinical study; overall survival; mortality; postoperative period; cancer combination chemotherapy; antineoplastic agents; united states; cancer adjuvant therapy; cancer staging; outcome assessment; follow up; lymph node metastasis; lymphatic metastasis; sensitivity analysis; prostate specific antigen; computer assisted tomography; retrospective study; cancer mortality; high risk patient; cancer survivor; prostate cancer; europe; gleason score; prostatic neoplasms; health care quality; cause of death; prostatectomy; cancer specific survival; clinical decision making; external beam radiotherapy; gonadorelin agonist; orchiectomy; observational study; androgen deprivation therapy; adjuvant radiotherapy; surgical margin; clinical target volume; comparative effectiveness; low risk patient; prognosis; human; male; priority journal; article; tertiary care center; mortality risk; hormonal
Journal Title: European Urology
Volume: 73
Issue: 6
ISSN: 0302-2838
Publisher: Elsevier Science, Inc.  
Date Published: 2018-06-01
Start Page: 890
End Page: 896
Language: English
DOI: 10.1016/j.eururo.2017.09.027
PROVIDER: scopus
PUBMED: 29042125
DOI/URL:
Notes: Article -- Export Date: 1 May 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Peter T Scardino
    613 Scardino
  2. Abdelkrim Karim Touijer
    190 Touijer
  3. Andrew J Vickers
    538 Vickers
  4. Daniel D. Sjoberg
    133 Sjoberg
  5. James Eastham
    420 Eastham
  6. Melissa Jean Assel
    33 Assel